The commercial release of 3D printed liver tissue was announced earlier this week. Organovo is the company behind the release. The product is intended for use for preclinical drug discovery testing to see if the drugs are toxic or not. This is intended to provide data to help predict liver tissue toxicity or ADME (absorption, distribution, metabolism and excretion) outcomes in later-stage preclinical drug discovery programs. The product is called exVive3D Human Liver Tissue. According to the company, "The durability and functionality of the 3D liver product enable the assessment of the effects of low dose or repeated dosing regimens across a spectrum of biochemical, molecular, and histologic end points.".
For more information, please visit: freedawn.co.uk/scientia/2014/11/21/organovo-has-3…r-drug-testing/
- Organovo has 3D printed liver tissue for drug testing ( Download)
- Organovo releases 3D-printed human liver tissue ( Download)
- 3D printing: The future of organ transplants ( Download)
- 3D-printer: Organovo to manufacture liver tissues ( Download)
- Introduction to Organovo ( Download)
- Organovo ( Download)
- Webinar: 3D Bioprinted Therapeutic Liver Tissue ( Download)
- Organovo ( Download)
- Webinar: 3D Bioprinted Kidney Tissue for Evaluation of Drug-Induced Toxicity ( Download)
- Webinar: Use of Bioprinted 3D Human Tissues for the Assessment of Drug Toxicity ( Download)
- Organovo ( Download)
- 3D printed organs being used to test vaccines ( Download)
- Company Profile: Organovo ( Download)
- Webinar: Modeling NAFLD and TGFbeta-induced Fibrosis in ExVive™ Human Liver Tissue ( Download)
- KPMGVoice: Organovo - The Great Rewrite (Chapter 1) | Forbes ( Download)